Richardpruen (talk | contribs) (→Suggested studies to add to this page: Added UK government latest policy write up in BMJ) |
Richardpruen (talk | contribs) (Added study) |
||
| Line 45: | Line 45: | ||
=Continuum of Risk= | =Continuum of Risk= | ||
=== 2023: [https://pubmed.ncbi.nlm.nih.gov/37061812/ Nicotine - friend or foe? The complex interplay between its role in dependence, harm reduction and risk communication.] === | |||
* So, how should we communicate the risks of nicotine? The quixotic attitude towards nicotine in our field has unintended consequences elsewhere. O’Brien et al.’s study of adolescents in the PATH study confirms findings in adults, including medical professionals, that nicotine is believed to cause smoking-related harms beyond addiction, such as cancer. Encouragingly, those having higher risk perceptions were less likely to start using nicotine-containing products a year later. Concerningly, even among adolescent smokers nearly half believed that nicotine in NRT was harmful, which may reduce the use of effective medication to help them stop smoking. | |||
* Clearly, no one wants to see a generation of nicotine-dependent youth, and more effective measures to limit access to nicotine, especially combustible nicotine, are needed. But when it comes to communicating research to the wider public, we must avoid conflating the relatively limited harm of nicotine dependence with its effects on maintaining tobacco addiction, and therefore well-established tobacco-related harm, not least because of the impact this has on risk perceptions of those most in need of nicotine-based treatment: Tobacco users. | |||
* This is a valuable commentary because it acknowledges the concerns about nicotine use and dependence, but points out the major danger in overemphasizing the associated risks (perpetuating the most harmful form of nicotine). There seems to be a common ends-justify-the-means attitude that condones or even encourages greater risk perceptions (especially among youth) in the hopes that it will deter them from using nicotine, but Dr. Shahab points out the obvious public health risks of this as well. | |||
* Shahab L. Nicotine Tob Res. 2023 Apr 15:ntad053. doi: 10.1093/ntr/ntad053. Online ahead of print. PMID: 37061812 No abstract available. | |||
===[https://pubmed.ncbi.nlm.nih.gov/32155137/ 2020: E-cigarettes and their impact on health: from pharmacology to clinical implications]=== | ===[https://pubmed.ncbi.nlm.nih.gov/32155137/ 2020: E-cigarettes and their impact on health: from pharmacology to clinical implications]=== | ||
edits